Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones


INSIDE INFORMATION
REGULATED INFORMATION

Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones
All 115 patients implanted in DREAM U.S. pivotal study
First DREAM PMA module submitted
First patient implanted in ACCCESS U.S. pivotal study

Mont-Saint-Guibert, Belgium – March 6, 2023, 7:30am CET / 1:30am ET – Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) (“Nyxoah” or the “Company”), a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA), today announced that the Company has completed all 115 implants in its DREAM U.S. pivotal study, submitted the first module in the modular PMA submission and implanted the first patient in the ACCCESS U.S. pivotal study. 

The DREAM study is a pivotal, investigational device exemption (IDE) trial designed to support the marketing authorization of the Genio® hypoglossal nerve stimulation system (HGNS) in the United States. This multicenter, prospective, open-label, observational study enrolled 115 patients and has co-primary efficacy endpoints of the Apnea-Hypopnea Index (AHI) responder rate, per the Sher criteria, and the Oxygen Desaturation Index (ODI) responder rate, both at 12 months.

In the ACCCESS trial, Nyxoah will implant 106 complete concentric collapse (CCC) patients with co-primary efficacy endpoints of Apnea-Hypopnea Index (AHI) responder rate, per the Sher criteria, and Oxygen Desaturation Index (ODI) responder rate, both assessed at 12 months post-implant.  

“The achievement of these key clinical and regulatory milestones brings us closer to offering our patient centric Genio solution to all OSA patients in the U.S. The DREAM and ACCCESS studies demonstrate Nyxoah’s mission of providing Genio to patients regardless of CCC status and without the requirement for a CCC diagnosis,” commented Olivier Taelman, Nyxoah’s Chief Executive Officer.

About Nyxoah
Nyxoah is a medical technology company focused on the development and commercialization of innovative solutions to treat Obstructive Sleep Apnea (OSA). Nyxoah’s lead solution is the Genio® system, a patient-centered, leadless and battery-free hypoglossal neurostimulation therapy for OSA, the world’s most common sleep disordered breathing condition that is associated with increased mortality risk and cardiovascular comorbidities. Nyxoah is driven by the vision that OSA patients should enjoy restful nights and feel enabled to live their life to its fullest. 

Following the successful completion of the BLAST OSA study, the Genio® system received its European CE Mark in 2019. Following the positive outcomes of the BETTER SLEEP study, Nyxoah received CE mark approval for the expansion of its therapeutic indications to Complete Concentric Collapse (CCC) patients, currently contraindicated in competitors’ therapy. Additionally, the Company is currently conducting the DREAM IDE pivotal study for FDA and US commercialization approval.

For more information, please visit http://www.nyxoah.com/.

Caution – CE marked since 2019. Investigational device in the United States. Limited by U.S. federal law to investigational use in the United States.

Forward-looking statements 
Certain statements, beliefs and opinions in this press release are forward-looking, which reflect the Company's or, as appropriate, the Company directors' or managements' current expectations regarding the Genio® system; future financial performance and market position; planned and ongoing clinical studies of the Genio® system; the potential advantages of the Genio® system; Nyxoah’s goals with respect to the development, regulatory pathway and potential use of the Genio® system; the utility of clinical data in potentially obtaining FDA approval of the Genio® system; and the Company's results of operations, financial condition, liquidity, performance, prospects, growth and strategies. By their nature, forward-looking statements involve a number of risks, uncertainties, assumptions and other factors that could cause actual results or events to differ materially from those expressed or implied by the forward-looking statements. These risks, uncertainties, assumptions and factors could adversely affect the outcome and financial effects of the plans and events described herein. Additionally, these risks and uncertainties include, but are not limited to, the risks and uncertainties set forth in the “Risk Factors” section of the Company’s Annual Report on Form 20-F for the year ended December 31, 2021, filed with the Securities and Exchange Commission (“SEC”) on March 24, 2022, and subsequent reports that the Company files with the SEC. A multitude of factors including, but not limited to, changes in demand, competition and technology, can cause actual events, performance or results to differ significantly from any anticipated development. Forward looking statements contained in this press release regarding past trends or activities are not guarantees of future performance and should not be taken as a representation that such trends or activities will continue in the future. In addition, even if actual results or developments are consistent with the forward-looking statements contained in this press release, those results or developments may not be indicative of results or developments in future periods. No representations and warranties are made as to the accuracy or fairness of such forward-looking statements. As a result, the Company expressly disclaims any obligation or undertaking to release any updates or revisions to any forward-looking statements in this press release as a result of any change in expectations or any change in events, conditions, assumptions or circumstances on which these forward-looking statements are based, except if specifically required to do so by law or regulation. Neither the Company nor its advisers or representatives nor any of its subsidiary undertakings or any such person's officers or employees guarantees that the assumptions underlying such forward-looking statements are free from errors nor does either accept any responsibility for the future accuracy of the forward-looking statements contained in this press release or the actual occurrence of the forecasted developments. You should not place undue reliance on forward-looking statements, which speak only as of the date of this press release.

Contacts:
David DeMartino
Chief Strategy Officer
david.demartino@nyxoah.com
+1 310 310 1313


Attachment

  • ENGLISH_Nyxoah Announces a Clinical Update


Nyxoah Announces Achievement of Key Clinical and Regulatory Milestones

THỦ THUẬT HAY

Xem mật khẩu đã lưu trên iOS 11

Bạn đang tìm mật khẩu và tài khoản đã lưu trên iPhone chạy iOS 11? Hãy đọc hướng dẫn xem mật khẩu đã lưu trên iOS 11 mới nhất này ngay nhé.

Hướng dẫn kết nối VPN tự động trên Linux

Có rất nhiều cách để kết nối với VPN từ hệ điều hành Linux. Tuy nhiên, nếu bạn muốn kết nối mà không cần tới GUI hoặc kết nối để chạy tự động thì hãy theo dõi bài viết dưới đây.

Hướng dẫn sạc pin laptop đúng cách, hiệu quả

Khi sử dụng laptop, việc chai pin sẽ luôn diễn ra. Tuy nhiên nếu bạn biết sạc pin laptop đúng thì sẽ hạn chế tối đa việc chai pin và kéo dài tuổi thọ pin hơn so với việc sạc thường.

20 câu nói truyền cảm hứng nổi tiếng nhất của Steve Jobs

'Đôi khi cuộc đời sẽ ném gạch vào đầu bạn. Đừng đánh mất niềm tin'.

Nhận ngay 50 phút gọi nội mạng miễn phí từ Viettel

Hôm nay TCN sẽ hưỡng dẫn độc giả từng bước để tham gia khuyến mại nạp 100.000 đ sẽ được cộng 50 phút gọi nội mạng đơn giản nhất.

ĐÁNH GIÁ NHANH

iPhone 13 giá bao nhiêu?Đặt trước ngay nhận ưu đãi cực sốc từ Viettel Store

Còn đúng 2 ngày nữa iPhone 13 series chính thức lên kệ tại thị trường Việt Nam. Đây là mẫu điện thoại được mong đợi nhất 2021, đặc biệt với các iFan. Chương trình đặt trước đã được triển khai và sẽ kết thúc vào ngày

Trên tay Honor X30i – Smartphone đẹp ngang tầm iPhone 13, giá chưa tới 5 triệu

iPhone 13 ra mắt người dùng với mức giá mà không phải ai đam mê công nghệ cũng có thể sở hữu. Tuy nhiên, trên tay Honor X30i – Bạn hoàn toàn có thể sở hữu một đẳng cấp với mức giá bất ngờ. Honor đã tạo ra bất ngờ khi

Galaxy A52s 5G: Thủ lĩnh học kỳ online với Video Camera Chống Rung Quang Học OIS cùng hiệu năng đỉnh cao

Một mùa tựu trường nữa lại sắp đến nhưng với một cách khác hẳn với những năm trước, với việc học sinh và sinh viên phải nhanh chóng thích nghi với việc “on” và “off” thì việc sở hữu một chiếc smartphone tiện dụng là vô